Pricing
  1. JP-listed companies
  3. Financials
  4. Total current assets

(E27038)

Market cap
P/E ratio
UMN Pharma develops innovative vaccines for infectious diseases like norovirus and rotavirus while providing contract manufacturing services for biopharmaceuticals.
SummaryFinancialsDividendsHistoryWorkforce
Period EndTotal current assets (Million JPY)YoY (%)
Dec 31, 20181,077-41.35%
Dec 31, 20171,837+182.54%
Dec 31, 2016650-26.32%
Dec 31, 2015882-59.49%
Dec 31, 20142,178-60.27%
Dec 31, 20135,482+24.51%
Dec 31, 20124,403

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat